Bio­gen re­vers­es course on com­pas­sion­ate use for ALS drug tofersen with plans to open pro­gram in Ju­ly

De­spite im­mense pres­sure from the ALS com­mu­ni­ty, Bio­gen had re­peat­ed­ly re­fused to open in­ves­ti­ga­tion­al drug tofersen for use out­side of clin­i­cal tri­als. But now, cav­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.